Sun City, Arizona 85351


Purpose:

This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with mild to moderate Alzheimer's disease. This study will evaluate the effects of 24 weeks of treatment with Thalidomide on plasma biomarkers.


Study summary:

A lumbar puncture will be done before treatment (baseline), and at 24 weeks to collect CSF for the quantification of biomarkers. As an exploratory effort, we will test the effects of thalidomide on the same biomarkers in the plasma and will determine if detectable changes mirror changes observed in the CSF.


Criteria:

Inclusion Criteria: - Subjects must have a screening diagnosis of Probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria. - Subjects must have a Mini-Mental State Examination (MMSE) score of 12-26 - Subject must live at home. - Must have a caregiver to participate in this study


NCT ID:

NCT01094340


Primary Contact:

Study Director
Carolyn Liebsack, BSN
Banner Sun Health Research Institute


Backup Contact:

N/A


Location Contact:

Sun City, Arizona 85351
United States

Marwan Sabbagh, MD
Phone: 623-832-6500
Email: marwan.sabbagh@bannerhealth.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: May 26, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.